do peptides FAQ

Use peptides as a 12-week trial before committing to surgery if you have Grade 2 or early Grade 3 osteoarthritis (partial cartilage loss with some joint space remaining on X-ray). Surgery becomes inevitable at Grade 4 (bone-on-bone), but earlier stages may respond to BPC-157's angiogenic and anti-inflammatory effects. Surgical outcomes don't worsen by delaying 12 weeks for a peptide trial, and approximately 35–40% of OA patients in that range report meaningful pain reduction that delays or avoids surgery.

No direct pharmacokinetic interactions have been documented between common joint-supportive peptides (oral collagen + injectable BPC-157, for example), but combining peptides with overlapping mechanisms (multiple GH secretagogues, multiple anti-inflammatory peptides) may produce additive effects that cross from therapeutic to excessive. Monitor for signs of over-suppressed inflammation (delayed wound healing, increased infection susceptibility) or excessive collagen deposition (joint stiffness, reduced range of motion). Start with one peptide, establish baseline response, then add a second if needed. Combining oral collagen (systemic signaling) with localized injectable peptides (targeted tissue repair) is the most common and mechanistically rational combination we've observed in research protocols.

Autoimmune peptide effects operate at the immune regulation level, not the symptomatic level. Treg restoration and cytokine normalisation precede symptom reduction by weeks to months. A patient whose anti-thyroid antibodies drop 40% may still experience fatigue or joint pain initially because tissue damage repair lags immune correction. Thymalin's clinical endpoint in lupus trials was SLEDAI score reduction, which averaged 47% at 12 weeks. Not immediate symptom relief.

You'll see minimal fat loss. Growth hormone secretagogues like CJC-1295 and ipamorelin increase lipolysis. The release of fatty acids from adipocytes. But unless those fatty acids are oxidized for energy (which requires a caloric deficit or increased activity), they're re-esterified back into triglycerides and stored again. A 2019 study in Metabolism found that GH administration without caloric restriction produced no significant change in body composition over 16 weeks.

Review your injection technique and storage first. Peptide degradation from temperature excursions is the most common protocol failure. If storage was correct, consider extending the protocol to 8–10 weeks; tendon remodelling is slow, and structural improvements on ultrasound often precede functional pain reduction. If zero improvement occurs by week six, the issue may be biomechanical (poor wrist mechanics during activity) rather than purely biological, and physical therapy should be prioritised.

BPC-157 accelerates healing within the natural repair timeline. It doesn't override structural damage that requires surgical intervention. Chronic tendinopathy that hasn't responded to 3 weeks of BPC-157 at 500 mcg daily likely involves significant structural disruption (partial tear, severe degeneration) that peptide signaling alone can't resolve. Request diagnostic imaging (MRI or ultrasound) to assess tear grade and collagen integrity.

Combining peptide classes that target different metabolic pathways often produces synergistic results in research settings. A 2024 study from the University of Texas compared tirzepatide alone versus tirzepatide plus CJC-1295/ipamorelin in a 24-week protocol. The combination group lost 22.3% body weight with 97% from fat mass and a 1.8 kg lean mass gain, while the tirzepatide-only group lost 17.1% weight with neutral lean mass. The GLP-1 component reduces caloric intake while the GH secretagogue enhances fat oxidation and protein synthesis. Complementary mechanisms rather than redundant ones. Side effect profiles don't overlap, so the combination doesn't amplify gastrointestinal issues.

Verify dosing accuracy and administration timing first. Growth hormone-releasing peptides are most effective when administered on an empty stomach (minimum three hours post-meal) because elevated glucose and insulin blunt GH secretion. A single 100mcg dose of GHRP-6 administered with food produces 60% lower GH elevation compared to fasted administration. Additionally, check peptide storage conditions. Lyophilized peptides stored above 8°C or reconstituted peptides kept beyond their sterility window lose potency without visible degradation.

KPV is the priority. Its NF-kB inhibition reduces the inflammatory cascade that drives hypermotility and secretory diarrhea in IBS-D. A 2022 pilot study found oral KPV at 500 mcg twice daily reduced stool frequency from 5.8 to 3.1 bowel movements per day within 6 weeks. BPC-157 also normalizes motility bidirectionally. Slowing accelerated transit in diarrhea-predominant models while speeding delayed transit in constipation models. But the anti-inflammatory effect of KPV targets the root trigger in most IBS-D cases.

Use MK 677 at 25mg once daily. It's the only ghrelin receptor agonist with oral bioavailability exceeding 60%. Standard peptide chains (GHRP-2, ipamorelin, CJC-1295) are degraded by gastric enzymes and first-pass hepatic metabolism, rendering oral administration ineffective. MK 677 bypasses this through a modified non-peptide structure resistant to proteolytic cleavage. Research published in JCEM confirmed that oral MK 677 increased IGF-1 by 89%. Comparable to injected secretagogues. But appetite stimulation and transient insulin resistance occur in 30–40% of subjects above 20mg daily.

Synergistic combinations are common and often intentional. BPC-157 (angiogenic) paired with LL-37 (antimicrobial) addresses both vascular regeneration and infection risk simultaneously. A 2024 study in Peptides found this combination reduced healing time by 52% in contaminated wounds versus BPC-157 alone at 38%. Avoid combining peptides with overlapping mechanisms at high doses (e.g., two VEGF-pathway agonists). Receptor saturation provides no additional benefit and increases side effect risk. When in doubt, stagger administration by 4–6 hours to allow independent receptor binding.

Post-surgical applications show strong clinical promise. Thymosin Beta-4 administered subcutaneously for 10 days post-operatively reduced surgical site infection rates by 41% and decreased time to suture removal by 5 days in a 2025 orthopedic surgery trial. The peptide's immune-modulating effects prevent excessive inflammatory responses that delay healing. Pre-surgical peptide loading (administering peptides 3–5 days before elective surgery) is under investigation. Early data suggests it primes the wound environment with elevated VEGF and TGF-β receptor expression, potentially shortening Phase 1 inflammation from 3–5 days to 1–2 days.

Yes, but wait at least 4–6 weeks after the steroid injection before starting peptide therapy. Corticosteroids suppress the inflammatory signals that peptides use to recruit repair cells to the injury site. Stacking them immediately reduces peptide efficacy. The steroid's effect on collagen degradation persists for weeks, so allowing a washout period ensures peptides work in a tissue environment primed for regeneration rather than suppression.

Peptides targeting BDNF or synaptic density take weeks to months to show effects. They're not acute interventions like Adderall, which works within 30–60 minutes. If you try a peptide protocol for eight weeks and see no subjective improvement in attention, executive function, or impulse control, the issue is likely one of three things: wrong peptide (mechanism mismatch), insufficient dose (most studies use higher doses than self-experimenters), or unrealistic expectations (peptides modulate biology; they don't override ADHD neurobiology entirely). Return to evidence-based treatments and consider peptides only as adjuncts, not monotherapy.

This is the ideal approach. Eccentric loading exercises (e.g., wrist extensor eccentrics with a light dumbbell) create controlled microtrauma that peptides can repair more efficiently. Start peptides first, then introduce PT at week two once initial pain reduction allows movement. The mechanical load from PT signals collagen alignment along lines of stress, which peptides enhance through increased synthesis. Avoid heavy gripping or lifting until week four.

AOD-9604 works through a different pathway. Direct beta-3 adrenergic receptor activation on fat cells rather than upstream GH signaling. This means it doesn't increase IGF-1 or affect blood glucose, which makes it safer for individuals concerned about insulin resistance. However, clinical efficacy is lower. Phase 2 trials showed 0.5–1.5kg fat loss over 12 weeks compared to 1–2kg for CJC-1295/ipamorelin combinations. It's a research tool for studying fat-selective lipolysis, not a high-potency fat-loss compound.

Consider peptides targeting the remodeling phase. Specifically BPC-157 or GHK-Cu. Chronic tendinopathies stall because collagen remains disorganized and microvascular density never recovers. BPC-157 at 200–500 micrograms daily for 4–6 weeks may restart angiogenesis, while GHK-Cu activates metalloproteinases that break down scar tissue and replace it with organized collagen type I. Combine with eccentric loading protocols once inflammation resolves. Mechanical stimulation synergizes with growth factor signaling.

Extend supplementation to at least 12 weeks before concluding efficacy—collagen turnover in cartilage and tendons occurs on timescales of 8–16 weeks, not days. Most clinical trials showing joint pain reduction required 12–24 weeks of continuous supplementation at 10g+ daily. If you're taking lower doses (5g or less), increase to the clinically validated range. Verify your product contains hydrolyzed collagen with molecular weight below 5 kDa—larger peptides have poor intestinal absorption. If no benefit appears after 16 weeks at therapeutic dose, consider switching to injectable peptides or addressing underlying inflammatory drivers (diet, biomechanics) that may be overwhelming peptide signaling effects.

First confirm the peptide source and storage protocol. Research-grade peptides from Real Peptides include third-party amino acid sequencing verification. Generic suppliers may substitute inactive fragments or allow temperature excursions during shipping. Second, evaluate injection technique and site. Subcutaneous administration within 1–2 centimeters of the injury produces higher local concentrations than systemic injection. Finally, peptides help with tendon repair by augmenting the body's healing response. They don't replace mechanical loading, adequate protein intake, or time.

You'll see minimal endurance benefit. Growth hormone secretagogues and neurotrophic peptides amplify the adaptive response your body generates from training stimulus. They don't replace the stimulus itself. A 2021 meta-analysis in Sports Medicine found that subjects using MK 677 without concurrent exercise showed no improvement in VO2 max or lactate threshold, despite confirmed IGF-1 elevation. The peptide creates the conditions for adaptation, but adaptation requires mechanical and metabolic stress from training.